Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, Özcan M, Samoilova O, Tolbert JA, Trudel GC, Xiu L, Vey N, Wei AH. Pabst T, et al. Among authors: papayannidis c. Lancet Haematol. 2023 Nov;10(11):e902-e912. doi: 10.1016/S2352-3026(23)00207-7. Lancet Haematol. 2023. PMID: 37914483 Clinical Trial.
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Defina M, Lazzarotto D, Guolo F, Minetto P, Fracchiolla NS, Giglio F, Forghieri F, Vitale A, Chiaretti S, Papayannidis C, Piccini M, Mulè A, Bocchia M, Leoncin M, Gurrieri C, Aprile L, Lunghi M, Bonifacio M, Pasciolla C, Cerrano M, Fumagalli M, Foà R, Candoni A. Defina M, et al. Among authors: papayannidis c. Leuk Res. 2022 Nov;122:106963. doi: 10.1016/j.leukres.2022.106963. Epub 2022 Sep 21. Leuk Res. 2022. PMID: 36155352 No abstract available.
New targets for Ph+ leukaemia therapy.
Martinelli G, Iacobucci I, Papayannidis C, Soverini S. Martinelli G, et al. Among authors: papayannidis c. Best Pract Res Clin Haematol. 2009 Sep;22(3):445-54. doi: 10.1016/j.beha.2009.08.002. Best Pract Res Clin Haematol. 2009. PMID: 19959093 Review.
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A; SPARK-AML1 Investigators. Kantarjian HM, et al. Among authors: papayannidis c. Cancer. 2013 Jul 15;119(14):2611-9. doi: 10.1002/cncr.28113. Epub 2013 Apr 19. Cancer. 2013. PMID: 23605952 Free PMC article. Clinical Trial.
A case report of acute myeloid leukemia and neurofibromatosis 1.
Sartor C, Papayannidis C, Chiara Abbenante M, Curti A, Polverelli N, Ottaviani E, Iacobucci I, Guadagnuolo V, Martinelli G. Sartor C, et al. Among authors: papayannidis c. Hematol Rep. 2013 Jul 3;5(2):28-9. doi: 10.4081/hr.2013.e8. Print 2013 Jun 28. Hematol Rep. 2013. PMID: 23888244 Free PMC article.
136 results